Using Aflibercept Injection to Treat Blood Vessel Growth Over the Cornea
Status:
Terminated
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
The cornea is the clear front part of the eye. Corneal neovascularization, the excessive
growth of blood vessels into the cornea, is a sight-threatening condition. Corneal
neovascularization is also a well recognized risk factor for corneal graft failure. The
current standard of care to prevent graft rejection includes use of topical steroids and
medicines that suppress the immune system. These medicines do not address corneal
neovascularization. The purpose of the study is to establish the safety and potential
efficacy of subconjunctival injections of aflibercept (EYLEA® , marketed by Regeneron)
injection in inducing regression of blood vessels growing into the cornea and promoting graft
survival.
This study is being conducted by Dr. Balamurali Ambati at the Moran Eye Center.